App-Quantinova.ai

Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes

E. Una Cidon - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Mucositis

Adrucil injection

Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy

J. Appleyard - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

FOLFIRINOX

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability

T. Kolarova - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases

S. Khakoo - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial

G. Abou-Alfa - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Infigratinib

A genetic custom-made in vivo drug screening platform for colorectal cancer patients

C. de Miguel - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Methadone hydrochloride

Understanding patient experience in hepatocellular carcinoma: A qualitative patient interview study

N. Patel - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

The screening and consensus based on practices and evidence (SCOPE) survey: Results of a real-world survey on metastatic colorectal cancer practice patterns

G. Prager - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Introduction of DYPD screening and its impact on treatment decisions: One centre's experience

A. Burnett - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Dihydropyrimidine dehydrogenase deficiency

N/A

Prognosis of patients presenting as carcinoma of unknown primary and effectiveness of acute oncology service: A single institution experience

M. Tuplin - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The outcomes and toxicity of FOLFIRINOX treatment in a cohort of patients with incurable pancreatic cancer treated in a single centre in Northern Ireland

O. Devlin - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

L-leucovorin

A single-centre experience of adjuvant oxaliplatin based chemotherapy in elderly stage II-III colorectal cancer patients

H. Reed - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Naïve indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer

S. Allerdice - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

Real-world experience of definitive chemoradiation in esophageal cancer: Correlation of tumour length, toxicity and disease control

F. Malik - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic ductal adenocarcinoma

R. Pihlak - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

Nerve fibers in the tumour microenvironment are co-localized with tertiary lymphoid structures and is associated with better survival in pancreatic cancer patients

L. Heij - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Effectiveness and safety of thermal ablation of pulmonary metastases in patients with colorectal cancer

N. Silva - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Real-world data study of BRAF mutant metastatic colorectal cancer patients across the Greater Manchester region prior to BEACON trial results

R. Cairns - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Self-reported prescribing practices in the setting of adjuvant treatment for colorectal cancer

C. Hanna - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Clinical outcomes of 49 consecutive patients admitted with malignant obstructive jaundice

S. Bukhari - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hyperbilirubinemia

N/A

Filters

45280 Abstracts